COVID-19 and reactions in the Norwegian population

Publications 2026

Hagen BS, Vlaisavljevic K, Oppedal LS, Endresen J, Mohn VS, Fladseth K, Lysaker TM, Ribe MP, Möller TF, Hole TL, Dahl J, Karlstad Ø, Gulseth HL, Olsen DB, Greve-Isdahl M, Watle SV, Estensen ME, Broch K, Haugaa KH, Hasselberg NE (2026)
Myocarditis after COVID-19 mRNA vaccination in Norway: a nationwide validation study
Open Heart, 13 (1)
DOI 10.1136/openhrt-2026-004112, PubMed 42082376

Magnúsdóttir I, Nygaard AB, Hoffart A, Murphy G, Kõiv K, Barker MM, Lovik A, Unnarsdóttir AB, Kähler AK, Hauksdóttir A, Thordardottir EB, Eyþórsson E, Gísladóttir EU, Joyce EE, Frans EM, Tómasson G, Hjördísar Jónsdóttir HL, Rúnarsdóttir H, Harðardóttir H, Dahl JA, Jakobsdóttir J, Kalleberg KT, Ásbjörnsdóttir KH, Ellingjord-Dale M, Istre MS et al. (2026)
Acute COVID-19 severity and impaired cognitive function up to 32 months after diagnosis: an observational study
BMC Med (in press)
DOI 10.1186/s12916-026-04856-2, PubMed 41965722

Bergstad Larsen V, Gunnes N, Gran JM, Dahl J, Bøås H, Viksmoen Watle S, Berild JD, Greve-Isdahl M, Størdal K, Løvdal Gulseth H, Karlstad Ø, Lopez-Doriga Ruiz P, Tapia G (2026)
Adverse events following SARS-CoV-2 mRNA vaccination in norwegian adolescents
Sci Rep, 16 (1)
DOI 10.1038/s41598-026-45261-2, PubMed 41896268